Related references
Note: Only part of the references are listed.Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients
Tim Svenstrup Poulsen et al.
APMIS (2021)
Colon Cancer, Version 2.2021
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Maurice Michel et al.
CANCERS (2021)
Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis
Tian Fang et al.
BMC GASTROENTEROLOGY (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
David Tamborero et al.
NATURE MEDICINE (2020)
Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer
Sun Young Kim et al.
ESMO OPEN (2020)
Immunocytochemistry for predictive biomarker testing in lung cancer cytology
Deepali Jain et al.
CANCER CYTOPATHOLOGY (2019)
Clinicopathological Significance of BRAFV600E Mutation in Colorectal Cancer: An Updated Meta-Analysis
Jianhua Wang et al.
JOURNAL OF CANCER (2019)
Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series
Amar Deshwar et al.
ANTICANCER RESEARCH (2018)
Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience
Nicky D’Haene et al.
Oncotarget (2018)
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao et al.
NATURE (2017)
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience
Jun Gong et al.
ONCOTARGET (2017)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas
Suzanne M. Crumley et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases
Umberto Malapelle et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Coming of age: ten years of next-generation sequencing technologies
Sara Goodwin et al.
NATURE REVIEWS GENETICS (2016)
ERBB2 Emerges as a New Target for Colorectal Cancer
Eirini Pectasides et al.
CANCER DISCOVERY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers
Nicky D'Haene et al.
PLOS ONE (2015)
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Christina Therkildsen et al.
ACTA ONCOLOGICA (2014)
Molecular Alterations and Biomarkers in Colorectal Cancer
William M. Grady et al.
TOXICOLOGIC PATHOLOGY (2014)
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
A. Rose Brannon et al.
GENOME BIOLOGY (2014)
Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells
Yuli Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
Olfa Derbel et al.
BMC CANCER (2013)
Technical and implementation issues in using next-generation sequencing of cancers in clinical practice
D. Ulahannan et al.
BRITISH JOURNAL OF CANCER (2013)
Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab
Benoit You et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer
Cecily P. Vaughn et al.
GENES CHROMOSOMES & CANCER (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Shahab Akhoondi et al.
CANCER RESEARCH (2007)
SMAD4 levels and response to 5-fluorouracil in colorectal cancer
P Alhopuro et al.
CLINICAL CANCER RESEARCH (2005)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
Share Paper
